ARTICANZ - Beta (ver 0.91)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - target/CDK4/6-inhibitor
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
target/CDK4/6-inhibitor
27
trial(s) found.
NCT07174336
Advanced
Phase 3
Recruiting
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY4064809 Combined With a CDK4/6 Inhibitor and Endocrine Therapy in Adults With HR+, HER2-Advanced Breast Cancer With a PIK3CA Mutation Who Received No Prior Treatment for Advanced Breast Cancer (PIKALO-2)
PI3Kalpha inhibitor,mutant selective,kinase/helical domain
placebo
+ CDK4/6 inhibitor
Breast cancer
Cancer
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2109 - North Ryde - Macquarie University Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3350 - Ballarat - Grampians Health Service's Ballarat Base Hospital
3630 - Shepparton - Goulburn Valley Health
QLD
4032 - Chermside - The Prince Charles Hospital
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital
WA
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital
NCT07100106
Advanced
Phase 1 / Phase 2
Recruiting
A Phase Ib/II Multicenter, Open-Label, Randomized Study Evaluating the Safety, Pharmacokinetics, and Activity of GDC-4198 Alone and in Combination With Giredestrant in Comparison With Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive, HER2-Negative Breast Cancer Who Have Previously Progressed During or After a CDK4/6 Inhibitor (
GO46021
)
CDK2/4/6 inhibitor
CDK4/6 inhibitor
selective estrogen receptor degrader
Breast cancer
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
NCT07085767
Advanced
Phase 3
Recruiting
A Phase 3 Randomized, Double-Blind, Active-Controlled Study of Palazestrant With Ribociclib Versus Letrozole With Ribociclib for the First-Line Treatment of ER+, HER2- Advanced Breast Cancer (
OPERA-02
)
CDK4/6 inhibitor
aromatase inhibitor
complete estrogen receptor antagonist
Breast cancer
ER-positive breast cancer
HER2-negative breast cancer
NSW
2109 - North Ryde - Macquarie University Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3168 - Clayton - Monash Medical Centre
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6009 - Nedlands - Linear Clinical Research
NCT06760637
Advanced
Phase 3
Recruiting
AN INTERVENTIONAL, OPEN-LABEL, RANDOMIZED, MULTICENTER PHASE 3 STUDY OF PF-07220060 PLUS LETROZOLE COMPARED TO CDK4/6 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR (HR)-POSITIVE, HER2-NEGATIVE ADVANCED/METASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCED/METASTATIC DISEASE (
FOURLIGHT-3
)
CDK4 selective inhibitor
aromatase inhibitor
+ CDK4/6 inhibitor
Breast cancer
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health
3199 - Frankston - Peninsula Health Frankston Hospital
3940 - Capel Sound - Rosebud Hospital
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital
NCT06757634
Advanced
Phase 3
Recruiting
VIKTORIA-2: A Randomized, Open-Label, Phase 3 Study of Fulvestrant and CDK4/6 Inhibitors With or Without Gedatolisib as First-Line Treatment in Patients With HR-Positive and HER2-Negative Advanced Breast Cancer (
CELC-G-302
)
pan-PI3K/mTORC1/mTORC2 inhibitor
selective estrogen receptor degrader
+ CDK4/6 inhibitor
Breast cancer
NSW
2076 - Wahroonga - Sydney Adventist Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
QLD
4215 - Southport - ICON Cancer Care
SA
5000 - South Australia - GenesisCare St Andrews Hospital
5011 - Woodville South - The Queen Elizabeth Hospital
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT06736704
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1/2, Open-Label Dose Escalation and Expansion Study of SNV4818 as Monotherapy or in Combination With Other Anticancer Agents in Participants With Advanced Solid Tumors (
SNV4818-101
)
PI3K alpha inhibitor,allosteric,mutant-selective
+ CDK4/6 inhibitor
Breast cancer
Endometrial cancer
HPV-related cancer
Ovarian cancer
NSW
2031 - Randwick - Scientia Clinical Research Ltd
2050 - Camperdown - Chris O'Brien Lifehouse
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3168 - Clayton - Monash Medical Centre
WA
6009 - Nedlands - Linear Clinical Research
NCT06726148
Advanced
Phase 1 / Phase 2
Recruiting
An Open-label, Multi-center, Phase I/II Study of ECI830 as a Single Agent and in Combination With Ribociclib and Endocrine Therapy in Patients With Advanced Hormone Receptor Positive, HER2-negative Breast Cancer and Advanced Solid Tumors (
CECI830A12101
)
CDK2 inhibitor
CDK4/6 inhibitor
Breast cancer
Solid tumour
VIC
3004 - Melbourne, Southbank - Alfred Health
3168 - Clayton - Monash Medical Centre
NCT06625775
Advanced
Phase 1
Recruiting
A Phase 1a/1b Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of BBO-10203 in Subjects With Advanced Solid Tumors (The BREAKER-101 Study) (
TBBO10203-101
)
PI3K alpha-RAS breaker
+ CDK4/6 inhibitor
Breast cancer
Colorectal cancer
HER2-negative breast cancer
HER2-positive breast cancer
Non-small cell lung cancer
RAS-mutant colorectal cancer
NSW
2031 - Randwick - Scientia Clinical Research Ltd
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
NCT06380751
Advanced
Phase 3
Recruiting
A Randomised, Open-Label, Phase III Study of Saruparib (AZD5305) Plus Camizestrant Compared With Physician's Choice CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant for the First-Line Treatment of Patients With BRCA1, BRCA2, or PALB2 Mutations and Hormone Receptor Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified) Advanced Breast Cancer (EvoPAR-Breast01) (
EvoPAR-BR01
)
PARP1-selective inhibitor
selective estrogen receptor degrader
+ CDK4/6 inhibitor
Breast cancer
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
NCT06188520
Advanced
Phase 1 / Phase 2
Recruiting
A Phase I/IIa, First-in-human, Open-label, Dose Escalation and Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors (
CYCAD-1
)
CDK2 inhibitor
+ CDK4/6 inhibitor
Breast cancer
High-grade serous ovarian cancer
VIC
3002 - East Melbourne - Epworth Freemasons
NCT06065748
Curative
Phase 3
Recruiting
A Phase III Randomized, Open-Label Study Evaluating Efficacy and Safety of Giredestrant Compared With Fulvestrant, Both Combined With a CDK4/6 Inhibitor, in Patients With Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer With Resistance to Prior Adjuvant Endocrine Therapy (
CO44657
)
selective estrogen receptor degrader
+ CDK4/6 inhibitor
ER-positive HER2-negative breast cancer
NSW
2060 - North Sydney - Mater Hospital
2086 - Frenchs Forest - Northern Beaches Hospital
2747 - Kingswood - Nepean Hospital - Nepean Cancer Care Centre
VIC
3021 - St Albans - Western Health - Sunshine Hospital
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong
3280 - Warrnambool - South West Healthcare, Warrnambool Base Hospital, Oncology Unit
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
NA
NA
NZ
NZ.0110 - Whangarei - Whangarei Hospital
NZ.4442 - Roslyn - Palmerston North Hospital Cancer Centre - Palmerston North Hospital
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre
NCT05999994
Paed
Phase 2
Recruiting
CAMPFIRE
: Children's and Young Adult Master Protocol for Innovative Pediatric Research
Abemaciclib
CDK4/6 inhibitor
CDK4 inhibitor
CDK6 inhibitor
Cyclophosphamide
Docetaxel
Gemcitabine
Irinotecan
Ramucirumab
Temozolomide
Vinorelbine
alkylating agent
anti-VEGFR2 monoclonal antibody
antimetabolite
cancer therapy
cancer therapy,CDK4-targeting
cancer therapy,CDK6-targeting
cancer therapy,VEGFR2-targeting
cytotoxic chemotherapy
immuno-oncology therapy,VEGFR2-targeting
taxane
topoisomerase inhibitor
vinca alkaloid
+ CDK4/6 inhibitor
Cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2145 - Westmead - The Children's Hospital at Westmead
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health
NCT05952557
Curative
Phase 3
Recruiting
CAMBRIA-2
: A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-High or High Risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease
selective estrogen receptor degrader
selective estrogen receptor modulator
+ CDK4/6 inhibitor
Breast cancer
NSW
2031 - Randwick - Prince of Wales Hospital
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2170 - Liverpool - Liverpool Hospital
2200 - Bankstown - Bankstown-Lidcombe Hospital
2290 - Gateshead - Genesis Cancer Care, Lake Macquarie Private Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
2450 - Coffs Harbour - Coffs Harbour Health Campus - The North Coast Cancer Institute
2500 - Wollongong - Wollongong Hospital
2576 - Bowral - Southern Highlands Cancer Centre
ACT
2605 - Garran - The Canberra Hospital
VIC
3004 - Melbourne, Southbank - Alfred Health
3065 - Fitzroy - St Vincent's Hospital Melbourne
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3121 - Richmond - Epworth Freemasons Hospital
3168 - Clayton - Monash Medical Centre
3186 - Brighton - Cabrini Hospital Brighton Cancer Centre
3199 - Frankston - Peninsula Health Frankston Hospital
3280 - Warrnambool - South West Healthcare, Warrnambool Base Hospital, Oncology Unit
3550 - Bendigo - Bendigo Health - Bendigo Cancer Centre
3630 - Shepparton - Goulburn Valley Health
3677 - Wangaratta - Northeast Health Wangaratta
3844 - Traralgon - Latrobe Regional Hospital
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital
6150 - Murdoch - Fiona Stanley Hospital
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NZ.3210 - Hamilton - Waikato Hospital
NZ.4442 - Roslyn - Palmerston North Hospital Cancer Centre - Palmerston North Hospital
NCT05867251
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1/2, First-in-Human Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of AVZO-021 as a Single Agent and in Combination Therapy in Patients With Advanced Solid Tumors (
AVZO-021-1001
)
CDK2 inhibitor
+ CDK4/6 inhibitor
Breast cancer
Endometrial cancer
Epithelial Ovarian Cancer
Fallopian tube cancer
Ovarian cancer
Primary fallopian tube serous carcinoma
Primary peritoneal serous carcinoma
Solid tumour
Triple-negative breast cancer
NSW
2109 - North Ryde - Macquarie University Hospital
2500 - Wollongong - Cancer Care Wollongong
NCT05843253
Paed
Phase 2
Recruiting
Phase 2 Study of Ribociclib-Containing Post-Radiotherapy Combinations in Pediatric and Young Adult Patients Newly Diagnosed With High-Grade Glioma, Including Diffuse Intrinsic Pontine Glioma: Ribociclib and Everolimus for HGG/DIPG Which Harbor Alterations of the Cell Cycle and/or PI3K/mTOR Pathways AND Ribociclib and Temozolomide for DHG, H3G34-mutant (
CONNECT-TarGeT-A
)
CDK4/6 inhibitor
alkylating agent
mTORC1 inhibitor
radiotherapy
Anaplastic astrocytoma
Central nervous system cancer
Diffuse hemispheric glioma
Diffuse intrinsic pontine glioma
Glioblastoma
Glioma
H3K27M-mutant glioma
High-grade glioma
NSW
2031 - Randwick - Sydney Children's Hospital
VIC
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health
QLD
4101 - South Brisbane - Queensland Children's Hospital
WA
6009 - Perth - Perth Children's Hospital
NZ
NZ.1023 - Grafton - Starship Children's Hospital
NCT05827081
Curative
Phase 3
Recruiting
A Phase IIIb Study to Characterize the Efficacy and Safety of Adjuvant Ribociclib Plus Endocrine Therapy in a Close-to-clinical Practice Patient Population With HR+ HER2- Early Breast Cancer (Adjuvant WIDER) (
Adjuvant-WIDER
)
CDK4/6 inhibitor
Breast cancer
NT
0810 - Tiwi, Royal Darwin Hospital - Northern Centre for Oncology
NSW
2290 - Gateshead - Genesis Cancer Care, Lake Macquarie Private Hospital
VIC
3002 - East Melbourne - Epworth Freemasons
3168 - Clayton - Monash Medical Centre
NCT05735080
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1/2, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of INX-315 in Patients With Advanced Cancer (
INX-315-01
)
CDK2 inhibitor
+ CDK4/6 inhibitor
Breast cancer
Cancer
Carcinoma
Ovarian cancer
Solid tumour
VIC
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
NCT05696626
Advanced
Phase 3
Recruiting
An Open Label, Randomized, Multicenter Study Comparing the Efficacy and Safety of the Combination of Lasofoxifene and Abemaciclib to the Combination of Fulvestrant and Abemaciclib for the Treatment of Pre- and Postmenopausal Women and Men With Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation (
ELAINEIII
)
CDK4/6 inhibitor
selective estrogen receptor degrader
selective estrogen receptor modulator
Breast cancer
NSW
2139 - Concord - Concord Repatriation General Hospital
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
NCT05563220
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1b/2, Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Patients With Metastatic Breast Cancer (
ELEVATE
)
selective estrogen receptor degrader
+ CDK4/6 inhibitor
Breast cancer
NSW
2109 - North Ryde - Macquarie University Hospital
NCT05508906
Advanced
Phase 1
Recruiting
A Phase 1b Open-Label Multicenter Study of OP-1250 (Palazestrant) in Combination With the CDK4/6 Inhibitor Ribociclib, With the PI3K Inhibitor Alpelisib, With the mTOR Inhibitor Everolimus, or With CDK4 Inhibitor Atirmociclib in Adult Subjects With Advanced and/or Metastatic ER Positive, HER2 Negative Breast Cancer (
OP-1250-003
)
CDK4/6 inhibitor
CDK4 selective inhibitor
PI3K alpha inhibitor
complete estrogen receptor antagonist
mTORC1 inhibitor
Breast cancer
ER-positive breast cancer
HER2-negative breast cancer
NSW
2109 - North Ryde - Macquarie University Hospital
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT05216432
Advanced
Phase 1
Recruiting
First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer (
RLY-2608-101
)
PI3K alpha inhibitor,allosteric,mutant-selective
+ CDK4/6 inhibitor
Breast cancer
HER2-negative breast cancer
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3004 - Melbourne, Southbank - Alfred Health
NCT05203172
Advanced
Phase 4
Recruiting
ENCORAFENIB/BINIMETINIB MASTER PROTOCOL: AN OPEN-LABEL CONTINUATION STUDY FOR PARTICIPANTS CONTINUING FROM ENCORAFENIB/BINIMETINIB CLINICAL STUDIES (
C4221026
)
BRAF V600 inhibitor
MEK inhibitor
+ CDK4/6 inhibitor
Solid tumour
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
NCT04862663
Advanced
Phase 3
Recruiting
A Phase Ib/III, Open-label, Randomised Study of Capivasertib Plus CDK4/6 Inhibitors and Fulvestrant Versus CDK4/6 Inhibitors and Fulvestrant in Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced, Unresectable or Metastatic Breast Cancer (
CAPItello-292
)
pan-AKT inhibitor
selective estrogen receptor degrader
+ CDK4/6 inhibitor
Breast cancer
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2076 - Wahroonga - Sydney Adventist Hospital
2228 - Miranda - Southside Cancer Care Centre
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT04802759
Advanced
Phase 1 / Phase 2
Recruiting
A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Breast Cancer (MORPHEUS-BREAST CANCER) (
CO42867
)
AKT inhibitor
Abemaciclib
Atezolizumab
CDK4/6 inhibitor
CDK4 inhibitor
CDK6 inhibitor
CDK7 inhibitor
ER degrader
Everolimus
Giredestrant
Inavolisib
Ipatasertib
PI3K alpha inhibitor
Palbociclib
Pertuzumab
Ribociclib
Samuraciclib
anti-ERBB2 monoclonal antibody
anti-ERBB2 monoclonal antibody,dimerization inhibitor
anti-PD-L1 monoclonal antibody
cancer therapy
cancer therapy,AKT-targeting
cancer therapy,CDK4-targeting
cancer therapy,CDK6-targeting
cancer therapy,CDK7-targeting
cancer therapy,ERBB2-targeting
cancer therapy,ESR1-targeting
cancer therapy,PD-1/PD-L1-targeting
cancer therapy,PD-L1-targeting
cancer therapy,PI3Kalpha-targeting
cancer therapy,mTOR-targeting
cancer therapy,mTORC1-targeting
endocrine therapy
endocrine therapy,oestrogen axis-targeting
immune checkpoint blockade
immune checkpoint blockade,PD-L1-targeting
immuno-oncology therapy,ERBB2-targeting
immuno-oncology therapy,PD-L1-targeting
mTORC1 inhibitor
mTOR inhibitor
oestrogen receptor-targeting therapy
pan-AKT inhibitor
selective estrogen receptor degrader
+ CDK4/6 inhibitor
Breast cancer
ER-positive breast cancer
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3199 - Frankston - Peninsula Health Frankston Hospital
SA
5042 - Bedford Park - Flinders Medical Centre
WA
6009 - Nedlands - Linear Clinical Research
NCT04606446
Advanced
Phase 1
Recruiting
A PHASE 1/2A DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY, TOLERABILITY, PHARMACOKINETIC, PHARMACODYNAMIC, AND ANTI-TUMOR ACTIVITY OF PF-07248144 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS (
KAT6
)
KAT6A/B inhibitor
KAT6 inhibitor
+ CDK4/6 inhibitor
Breast cancer
Castrate-resistant prostate cancer
Non-small cell lung cancer
Prostate cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3021 - St Albans - Western Health - Sunshine Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital
NCT03424005
Advanced
Phase 1 / Phase 2
Recruiting
A Phase Ib/II, Open-label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic Breast Cancer (
Morpheus-panBC
)
AKT inhibitor
Abemaciclib
Atezolizumab
Atirmociclib
Bevacizumab
CDK4/6 inhibitor
CDK4 inhibitor
CDK4 selective inhibitor
CDK6 inhibitor
Capecitabine
Carboplatin
ER degrader
Eribulin
Fulvestrant
Gemcitabine
Inavolisib
Ipatasertib
Ladiratuzumab Vedotin
Letrozole
Metformin
Nab-paclitaxel
PI3K alpha inhibitor
Palbociclib
Ribociclib
Sacituzumab Govitecan
Selicrelumab
Tocilizumab
Trastuzumab Deruxtecan
agnostic antibody,CD40-targeting
anti-CD40 agonistic antibody
anti-ERBB2 antibody-drug conjugate
anti-IL-6 monoclonal antibody
anti-LIV1 antibody-drug conjugate
anti-PD-L1 monoclonal antibody
anti-Trop2 antibody-drug conjugate
anti-VEGF monoclonal antibody
antimetabolite
aromatase inhibitor
biguanide antihyperglycaemic agent
cancer therapy
cancer therapy,AKT-targeting
cancer therapy,CD40-targeting
cancer therapy,CDK4-targeting
cancer therapy,CDK4 selective-targeting
cancer therapy,CDK6-targeting
cancer therapy,ERBB2-targeting
cancer therapy,ESR1-targeting
cancer therapy,IL-6-targeting
cancer therapy,LIV1-targeting
cancer therapy,PD-1/PD-L1-targeting
cancer therapy,PD-L1-targeting
cancer therapy,PI3Kalpha-targeting
cancer therapy,Trop2-targeting
cancer therapy,VEGF-targeting
cytotoxic chemotherapy
endocrine therapy
endocrine therapy,oestrogen axis-targeting
fluoropyrimidine
immune checkpoint blockade
immune checkpoint blockade,PD-L1-targeting
immuno-oncology therapy,CD40-targeting
immuno-oncology therapy,ERBB2-targeting
immuno-oncology therapy,IL-6-targeting
immuno-oncology therapy,LIV1-targeting
immuno-oncology therapy,PD-L1-targeting
immuno-oncology therapy,Trop2-targeting
immuno-oncology therapy,VEGF-targeting
macrocyclic ketone analogue
oestrogen receptor-targeting therapy
pan-AKT inhibitor
platinum-based antineoplastic agent
selective estrogen receptor degrader
taxane
+ CDK4/6 inhibitor
Breast cancer
VIC
3002 - Melbourne - Peter MacCallum Cancer Centre, East Melbourne campus
WA
6150 - Murdoch - Fiona Stanley Hospital
ACTRN12621000991819
Advanced
Not Applicable
Status unknown
A Feasibility Trial of Patient Derived Cell Culture (PDCC) Chemosensitivity in Head and Neck Carcinoma (HNC) (
PDCCiHNC
)
ALK inhibitor
ALK inhibitor,first generation
ATR inhibitor
BCR-ABL1 inhibitor
BCR-ABL1 inhibitor,second generation
CDK4/6 inhibitor
CDK4 inhibitor
CDK6 inhibitor
CRAF/FLT3/KIT/PDGFR/VEGFR inhibitor
CRAF inhibitor
Carboplatin
Ceralasertib
Cisplatin
Crizotinib
Dactolisib
Dasatinib
Docetaxel
Doxorubicin
EGFR inhibitor
EGFR inhibitor,first generation
Erlotinib
Etoposide
FLT3 inhibitor
Fluorouracil
Gemcitabine
Itraconazole
JAK1/JAK2 inhibitor
JAK1 inhibitor
JAK2 inhibitor
KIT inhibitor
MET inhibitor
MET inhibitor,type 1
Methotrexate
PDGFRA inhibitor
PDGFR inhibitor
PI3K/mTOR inhibitor
PI3K inhibitor
Paclitaxel
Palbociclib
Pemetrexed
RAF inhibitor
ROS1 inhibitor
Ruxolitinib
SMO inhibitor
SRC inhibitor
Sorafenib
VEGFR inhibitor
Vinorelbine
Vistusertib
YES1 inhibitor
anthracycline
antifolate
antimetabolite
cancer therapy
cancer therapy,ALK-targeting
cancer therapy,ATR-targeting
cancer therapy,BCR-ABL1-targeting
cancer therapy,CDK4-targeting
cancer therapy,CDK6-targeting
cancer therapy,CRAF-targeting
cancer therapy,EGFR-targeting
cancer therapy,FLT3-targeting
cancer therapy,JAK1-targeting
cancer therapy,JAK2-targeting
cancer therapy,KIT-targeting
cancer therapy,MET-targeting
cancer therapy,PDGFR-targeting
cancer therapy,PDGFRA-targeting
cancer therapy,PI3K-targeting
cancer therapy,RAF-targeting
cancer therapy,ROS1-targeting
cancer therapy,SMO-targeting
cancer therapy,SRC-targeting
cancer therapy,VEGFR-targeting
cancer therapy,YES1-targeting
cancer therapy,mTOR-targeting
cancer therapy,mTORC1-targeting
cancer therapy,mTORC2-targeting
cytotoxic chemotherapy
fluoropyrimidine
mTORC1/mTORC2 inhibitor
mTORC1 inhibitor
mTORC2 inhibitor
mTOR inhibitor
platinum-based antineoplastic agent
taxane
topoisomerase inhibitor
vinca alkaloid
+ CDK4/6 inhibitor
Head and neck cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (26)
Status unknown (1)
Recruitment Country and State
NSW (20)
VIC (19)
WA (11)
QLD (9)
SA (7)
NZ (3)
ACT (1)
NT (1)
Phase
Phase 1 (4)
Phase 1 / Phase 2 (9)
Phase 2 (2)
Phase 3 (10)
Phase 4 (1)
Trial Type
Advanced (22)
Curative (3)
Paed (2)
Cancer Therapy Class
CDK4
100%
CDK6
100%
oestrogen axis
85%
ER
78%
PI3Kalpha
33%
mTOR
22%
mTORC1
22%
CDK2
19%
CDK4 selective
19%
AKT
15%
ERBB2
11%
PI3K
7%
mTORC2
7%
VEGF
7%
Trop2
7%
EGFR
7%
RAF
7%
PD-1/PD-L1
7%
PD-L1
7%
PARP
4%
PARP1-selective
4%
LHRH
4%
VEGFR2
4%
GnRH
4%
androgen axis
4%
BRAF
4%
BRAF V600
4%
MEK
4%
CDK7
4%
KAT6A
4%
CD40
4%
IL-6
4%
LIV1
4%
ALK
4%
ATR
4%
BCR-ABL1
4%
CRAF
4%
FLT3
4%
JAK1
4%
JAK2
4%
KIT
4%
MET
4%
PDGFR
4%
PDGFRA
4%
ROS1
4%
SMO
4%
SRC
4%
VEGFR
4%
YES1
4%
Facility
3000 - Melbourne - Peter MacCallum Cancer Centre (10)
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre (5)
2109 - North Ryde - Macquarie University Hospital (5)
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre (5)
3168 - Clayton - Monash Medical Centre (5)
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre (5)
2298 - Waratah - Calvary Mater Newcastle Medical Oncology (4)
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health (4)
2050 - Camperdown - Chris O'Brien Lifehouse (4)
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital (3)
6009 - Nedlands - Linear Clinical Research (3)
3199 - Frankston - Peninsula Health Frankston Hospital (3)
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre (3)
3004 - Melbourne, Southbank - Alfred Health (3)
3630 - Shepparton - Goulburn Valley Health (2)
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital (2)
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong (2)
2076 - Wahroonga - Sydney Adventist Hospital (2)
2031 - Randwick - Scientia Clinical Research Ltd (2)
3002 - East Melbourne - Epworth Freemasons (2)
3021 - St Albans - Western Health - Sunshine Hospital (2)
3280 - Warrnambool - South West Healthcare, Warrnambool Base Hospital, Oncology Unit (2)
NZ.4442 - Roslyn - Palmerston North Hospital Cancer Centre - Palmerston North Hospital (2)
2290 - Gateshead - Genesis Cancer Care, Lake Macquarie Private Hospital (2)
6150 - Murdoch - Fiona Stanley Hospital (2)
3350 - Ballarat - Grampians Health Service's Ballarat Base Hospital (1)
4032 - Chermside - The Prince Charles Hospital (1)
3940 - Capel Sound - Rosebud Hospital (1)
4102 - Woolloongabba - Princess Alexandra Hospital (1)
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital (1)
4215 - Southport - ICON Cancer Care (1)
5000 - South Australia - GenesisCare St Andrews Hospital (1)
5011 - Woodville South - The Queen Elizabeth Hospital (1)
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre (1)
2060 - North Sydney - Mater Hospital (1)
2086 - Frenchs Forest - Northern Beaches Hospital (1)
2747 - Kingswood - Nepean Hospital - Nepean Cancer Care Centre (1)
NA
NZ.0110 - Whangarei - Whangarei Hospital (1)
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre (1)
2145 - Westmead - The Children's Hospital at Westmead (1)
2031 - Randwick - Prince of Wales Hospital (1)
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital (1)
2170 - Liverpool - Liverpool Hospital (1)
2200 - Bankstown - Bankstown-Lidcombe Hospital (1)
2450 - Coffs Harbour - Coffs Harbour Health Campus - The North Coast Cancer Institute (1)
2500 - Wollongong - Wollongong Hospital (1)
2576 - Bowral - Southern Highlands Cancer Centre (1)
2605 - Garran - The Canberra Hospital (1)
3065 - Fitzroy - St Vincent's Hospital Melbourne (1)
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre (1)
3121 - Richmond - Epworth Freemasons Hospital (1)
3186 - Brighton - Cabrini Hospital Brighton Cancer Centre (1)
3550 - Bendigo - Bendigo Health - Bendigo Cancer Centre (1)
3677 - Wangaratta - Northeast Health Wangaratta (1)
3844 - Traralgon - Latrobe Regional Hospital (1)
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research (1)
NZ.3210 - Hamilton - Waikato Hospital (1)
2500 - Wollongong - Cancer Care Wollongong (1)
2031 - Randwick - Sydney Children's Hospital (1)
4101 - South Brisbane - Queensland Children's Hospital (1)
6009 - Perth - Perth Children's Hospital (1)
NZ.1023 - Grafton - Starship Children's Hospital (1)
0810 - Tiwi, Royal Darwin Hospital - Northern Centre for Oncology (1)
2139 - Concord - Concord Repatriation General Hospital (1)
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre (1)
2228 - Miranda - Southside Cancer Care Centre (1)
5042 - Bedford Park - Flinders Medical Centre (1)
3002 - Melbourne - Peter MacCallum Cancer Centre, East Melbourne campus (1)
Cancer Type
Cancer
Solid tumour
Breast cancer
Breast adenocarcinoma
HER2-negative breast cancer
ER-positive breast cancer
HR-positive breast cancer
Gynaecological cancer
Ovarian cancer
Endometrial cancer
Lung cancer
Non-small cell lung cancer
Respiratory tract cancer
Thoracic cancer
Epithelial Ovarian Cancer
High-grade serous carcinoma of the ovary, fallopian tube, and peritoneum
HPV-related cancer
Viral-related cancer
Colorectal adenocarcinoma
Colorectal cancer
Gastrointestinal cancer
HER2-positive breast cancer
Lower gastrointestinal cancer
RAS-mutant colorectal cancer
High-grade serous ovarian cancer
Ovarian adenocarcinoma
Ovarian serous carcinoma
ER-positive HER2-negative breast cancer
Fallopian tube cancer
Peritoneal cancer
Primary fallopian tube serous carcinoma
Primary peritoneal serous carcinoma
Triple-negative breast cancer
Anaplastic astrocytoma
Central nervous system cancer
Diffuse hemispheric glioma
Diffuse intrinsic pontine glioma
Glioblastoma
Glioma
H3K27M-mutant glioma
High-grade glioma
Malignant glioma
Neurological cancer
Carcinoma
Castrate-resistant prostate cancer
Male genital cancers
Prostate adenocarcinoma
Prostate cancer
Urogenital cancer
Head and neck cancer
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy